disease, with the rationale being that perhaps we will detect an early ovarian cancer? ... prostate cancer, cannot.
high-grade prostatic carcinoma was reduced, but there was a possible increased risk in those who had prostate cancer, she said. ... When screening for prostate cancer in patients taking finasteride, Dr. Malerich suggested increasing the prostate-specific
We have evidence, and practitioners should use that to improve cancer screening rates. ... When Dr. Mulhausen told an 86-year-old man he didn't need to screen for prostate cancer, for example, the patient responded, “So you're just going to give up
In trials of patients with breast and prostate cancer, denosumab increased the length of time to SRE compared to zoledronic acid (Zometa). ... The breast cancer indication for bevacizumab was approved in February 2008 under the FDA's accelerated approval
Start with basic internal medicine. If an older patient with metastatic hormone-refractory prostate cancer has heart failure and shortness of breath, the best palliative care may be to treat his ... For instance, the patient may have a pulmonary embolism
Relugolix (Orgovyx) for the treatment of adult patients with advanced prostate cancer. ... In a randomized, open-label trial, 96.7% of 622 men with advanced prostate cancer who received the drug achieved and maintained low enough levels of testosterone.
for selecting a depression medication or deciding whether to have prostate cancer screening. ... Gutnick. Dr. Soung, for example, uses them for deciding about CT scans for lung cancer screening, medications for osteoporosis and depression, second-line
New warnings on gonadotropin-releasing hormone (GnRH) agonists about the potential risk of heart disease and diabetes in men treated with these medications for prostate cancer.
The therapy comes with its own potential risks, too, including a possible link to cardiovascular disease and prostate cancer.
Degarelix, a new injectable drug to treat advanced prostate cancer by suppressing testosterone. ... Imatinib mesylate (Gleevec), to stop cancer from growing after surgical removal of a gastrointestinal stromal tumor.